A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of HFB200301 in patients
with advanced cancers. There are two parts in this study. During the escalation part, groups
of participants will receive increasing doses until a safe and tolerable dose of HFB200301 is
determined. During the expansion part, participants will take the dose of study drug that was
determined from the escalation part of the study and will be assigned to a group based on the
type of cancer the participants have.